adc-13

ADC-13 ((5R,6S)-4-Nitrobenzyl 6-((R)-1-hydroxyethyl)-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate) is a p-nitrobenzyl ester β-lactam derivative, functioning as an intermediate in carbapenem antibiotic synthesis.

Nampt-IN-13 TFA is a NAMPT inhibitor (patent WO2021013693A1) suitable for synthesising antibody-drug conjugates (ADCs).

Bis-PEG13-NHS ester, a cleavable ADC linker, is utilized in the synthesis of antibody-drug conjugates (ADCs) [1].

Nampt-IN-13 (example 58m) is an NAMPT inhibitor used in the synthesis of antibody-drug conjugates (ADCs).

MC-Gly-Gly-Phe-Exatecan analog 38 (Compound L-II-4) forms part of an antibody-drug conjugate (drug-linker conjugate for ADC), consisting of an ADC cytotoxic component and an ADC linker. It can be utilized in synthesizing ADCs such as ADC-II-15 and ADC-III-13, and is applicable in cancer research.

Rha-PEG3-SMCC (Compound 13) serves as an ADC (antibody-drug conjugate) linkage agent with robust antitumor properties, utilizing the protein crosslinker SMCC, which is tethered through the non-cleavable linker Rha-PEG3.

cBu-Cit-PAB (Compound 13) serves as a crucial intermediate for ADC linkers. It is utilized in the synthesis of antibody-drug conjugates (ADCs).